These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 554063)

  • 1. ["Immune type" haemolysis in course of L. dopa-benserazide therapeutic (author's transl)].
    Conte P; Moulinier J; Reiffers J; Julien J
    Nouv Presse Med; 1979 Jan; 8(1):46-7. PubMed ID: 554063
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute non-haemolytic anemia after short administration of L Dopa plus Benserazide.
    Pezzoli G; Passerini D; Scarlato G; Radaelli F
    Ann Allergy; 1982 Jun; 48(6):362. PubMed ID: 7091780
    [No Abstract]   [Full Text] [Related]  

  • 3. [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
    Faglioni P; Gasparini M; Spinnler H
    Riv Patol Nerv Ment; 1975; 96(4):270-86. PubMed ID: 785578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Madopar in the treatment of paralysis agitans. I. Therapeutic efficacy and side-effects in 56 cases (author's transl)].
    Liu DK
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980; 13(3):147-50. PubMed ID: 7438902
    [No Abstract]   [Full Text] [Related]  

  • 5. [The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].
    Campanella G; Pennetta R
    Riv Patol Nerv Ment; 1974 Oct; 95(5):673-5. PubMed ID: 4470267
    [No Abstract]   [Full Text] [Related]  

  • 6. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 7. [Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
    Chouza C; Romero S; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):255-68. PubMed ID: 828242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Levodopa and decarboxylase inhibitors in Parkinson's disease].
    Gilland O
    Lakartidningen; 1977 Jan; 74(1-2):37-40. PubMed ID: 318722
    [No Abstract]   [Full Text] [Related]  

  • 9. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
    [No Abstract]   [Full Text] [Related]  

  • 10. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
    Mondal BK; Mondal KN
    Pharmatherapeutica; 1986; 4(9):571-6. PubMed ID: 3094036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of cramps of the lower extremities in patients with parkinsonism].
    Yu HZ
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):217-8. PubMed ID: 4075911
    [No Abstract]   [Full Text] [Related]  

  • 12. [5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602].
    Romero S; Chouza C; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):239-54. PubMed ID: 1018727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 14. ["Beginning and end of dose" dyskinesias caused by L-DOPA].
    Lhermitte F; Agid Y; Signoret JL; Studler JM
    Rev Neurol (Paris); 1977 May; 133(5):297-308. PubMed ID: 897439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-related levodopa-induced haemolytic anaemia.
    Linström FD; Liedén G; Enström MS
    Ann Intern Med; 1977 Mar; 86(3):298-300. PubMed ID: 402877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 17. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP; Kuss HJ; Rüther E
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract]   [Full Text] [Related]  

  • 18. Reversible haemolytic anaemia after levodopa-carbidopa.
    Bernstein RM
    Br Med J; 1979 Jun; 1(6176):1461-2. PubMed ID: 466061
    [No Abstract]   [Full Text] [Related]  

  • 19. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 20. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
    Dietrichson P
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2113-5. PubMed ID: 4590070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.